NCT07536815 2026-04-17
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
CytoDyn, Inc.
Available
Clinical Trials
5 trialsNCT04313075 2025-07-15
A Compassionate Use Study of Leronlimab in Breast Cancer
CytoDyn, Inc.
No longer available
NCT03123211 2022-05-24
Expanded Access to Veliparib
AbbVie
No longer available
NCT04320693 2021-08-19
Expanded Access for IMMU-132
Gilead Sciences
Approved for marketing
NCT01130259 2013-09-17
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
Sanofi
No longer available